Citation

Baker DE. Expert Review of Clinical Immunology 2009; 5(6): 683-691.

Copyright

(Copyright © 2009)

DOI

10.1586/eci.09.48

PMID

unavailable

Abstract

Certolizumab pegol is a polyethylene glycolated FAb fragment of a humanized anti-TNF-α monoclonal antibody. This pegylated molecule binds with circulating TNF-α and forms an inactive complex that is then eliminated from the body. The drug has been shown to be better than placebo in the treatment of Crohns disease and maintaining a clinical response in adult patients with moderate-to-severe active disease who have had an inadequate response to conventional therapy, and the treatment of adults with moderately to severely active rheumatoid arthritis. Comparative trials with an active control group are lacking. The most common adverse reactions include abdominal pain, diarrhea, injection site reactions and infection. All necessary live and attenuated vaccines should be given prior to the initiation of certolizumab pegol therapy, patients should be evaluated for TB risk factors and tested for latent TB prior to initiating therapy, and the initiation of therapy should be avoided if the patient has an active infection. Concomitant use with anakinra is not recommended because of the increased risk of serious infections and neutropenia. Therapy should be discontinued if the patient develops a serious infection during therapy. © 2009 Expert Reviews Ltd.

Language: en

Keywords

human; bipolar disorder; abdominal pain; anxiety; suicide attempt; heart failure; clinical trial; disease severity; kidney failure; risk factor; review; neutropenia; headache; macrogol; bleeding; heart infarction; tuberculosis; placebo; rheumatoid arthritis; seizure; diarrhea; nausea; leukopenia; drug withdrawal; fever; hypertension; side effect; infection; alopecia; heart arrhythmia; hepatitis; anemia; arthralgia; peripheral neuropathy; malignant neoplastic disease; antibiotic agent; immunoglobulin F(ab) fragment; azathioprine; dermatitis; angioneurotic edema; demyelinating disease; infection risk; intestine obstruction; aplastic anemia; dizziness; pancytopenia; urticaria; urinary tract infection; menstruation disorder; injection site inflammation; methotrexate; Crohn disease; injection site reaction; injection site erythema; injection site pain; prednisolone; upper respiratory tract infection; angina pectoris; uveitis; peripheral edema; lymphadenopathy; opportunistic infection; sore throat; vasculitis; hypersensitivity; mercaptopurine; lupus like syndrome; optic neuritis; pericardial effusion; serum sickness; TNF; rhinopharyngitis; nephritis; pericarditis; retina hemorrhage; erythema nodosum; certolizumab pegol; Certolizumab pegol; mesalazine; Crohns disease; Humanized anti-TNF-α monoclonal antibody; injection site burning; injection site rash; live vaccine; mycosis; PRECiSE 1 study; PRECiSE 2 study; recombinant interleukin 1 receptor blocking agent; thrombophilia